PURPOSE: To determine the reproducibility of measurements of brain 5-HT2A receptors with an [18F]altanserin PET bolus/infusion approach. Further, to estimate the sample size needed to detect regional differences between two groups and, finally, to evaluate how partial volume correction affects reproducibility and the required sample size. METHODS: For assessment of the variability, six subjects were investigated with [18F]altanserin PET twice, at an interval of less than 2 weeks. The sample size required to detect a 20% difference was estimated from [18F]altanserin PET studies in 84 healthy subjects. Regions of interest were automatically delineated on co-registered MR and PET images. RESULTS: In cortical brain regions with a high density of 5-HT2A receptors, the outcome parameter (binding potential, BP1) showed high reproducibility, with a median difference between the two group measurements of 6% (range 5-12%), whereas in regions with a low receptor density, BP1 reproducibility was lower, with a median difference of 17% (range 11-39%). Partial volume correction reduced the variability in the sample considerably. The sample size required to detect a 20% difference in brain regions with high receptor density is approximately 27, whereas for low receptor binding regions the required sample size is substantially higher. CONCLUSION: This study demonstrates that [18F]altanserin PET with a bolus/infusion design has very low variability, particularly in larger brain regions with high 5-HT2A receptor density. Moreover, partial volume correction considerably reduces the sample size required to detect regional changes between groups.
PURPOSE: To determine the reproducibility of measurements of brain 5-HT2A receptors with an [18F]altanserin PET bolus/infusion approach. Further, to estimate the sample size needed to detect regional differences between two groups and, finally, to evaluate how partial volume correction affects reproducibility and the required sample size. METHODS: For assessment of the variability, six subjects were investigated with [18F]altanserin PET twice, at an interval of less than 2 weeks. The sample size required to detect a 20% difference was estimated from [18F]altanserin PET studies in 84 healthy subjects. Regions of interest were automatically delineated on co-registered MR and PET images. RESULTS: In cortical brain regions with a high density of 5-HT2A receptors, the outcome parameter (binding potential, BP1) showed high reproducibility, with a median difference between the two group measurements of 6% (range 5-12%), whereas in regions with a low receptor density, BP1 reproducibility was lower, with a median difference of 17% (range 11-39%). Partial volume correction reduced the variability in the sample considerably. The sample size required to detect a 20% difference in brain regions with high receptor density is approximately 27, whereas for low receptor binding regions the required sample size is substantially higher. CONCLUSION: This study demonstrates that [18F]altanserin PET with a bolus/infusion design has very low variability, particularly in larger brain regions with high 5-HT2A receptor density. Moreover, partial volume correction considerably reduces the sample size required to detect regional changes between groups.
Authors: H W Müller-Gärtner; J M Links; J L Prince; R N Bryan; E McVeigh; J P Leal; C Davatzikos; J J Frost Journal: J Cereb Blood Flow Metab Date: 1992-07 Impact factor: 6.200
Authors: C H van Dyck; P Z Tan; R M Baldwin; L A Amici; P K Garg; C K Ng; R Soufer; D S Charney; R B Innis Journal: J Nucl Med Date: 2000-02 Impact factor: 10.057
Authors: G S Smith; J C Price; B J Lopresti; Y Huang; N Simpson; D Holt; N S Mason; C C Meltzer; R A Sweet; T Nichols; D Sashin; C A Mathis Journal: Synapse Date: 1998-12 Impact factor: 2.562
Authors: B Sadzot; C Lemaire; P Maquet; E Salmon; A Plenevaux; C Degueldre; J P Hermanne; M Guillaume; R Cantineau; D Comar Journal: J Cereb Blood Flow Metab Date: 1995-09 Impact factor: 6.200
Authors: Lars H Pinborg; Karen H Adams; Claus Svarer; Søren Holm; Steen G Hasselbalch; Steven Haugbøl; Jacob Madsen; Gitte M Knudsen Journal: J Cereb Blood Flow Metab Date: 2003-08 Impact factor: 6.200
Authors: Hans Rasmussen; Bjorn H Ebdrup; David Erritzoe; Bodil Aggernaes; Bob Oranje; Jan Kalbitzer; Lars H Pinborg; William F C Baaré; Claus Svarer; Henrik Lublin; Gitte M Knudsen; Birte Glenthoj Journal: Psychopharmacology (Berl) Date: 2010-07-08 Impact factor: 4.530
Authors: Eydie L Moses-Kolko; Julie C Price; Nilesh Shah; Sarah Berga; Susan M Sereika; Patrick M Fisher; Rhaven Coleman; Carl Becker; N Scott Mason; Tammy Loucks; Carolyn C Meltzer Journal: Neuropsychopharmacology Date: 2011-08-17 Impact factor: 7.853
Authors: René Hurlemann; Andreas Matusch; Kai-Uwe Kuhn; Julia Berning; David Elmenhorst; Oliver Winz; Heike Kolsch; Karl Zilles; Michael Wagner; Wolfgang Maier; Andreas Bauer Journal: Psychopharmacology (Berl) Date: 2007-09-27 Impact factor: 4.530
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944
Authors: Patrick J Riss; Young T Hong; David Williamson; Daniele Caprioli; Sergey Sitnikov; Valentina Ferrari; Steve J Sawiak; Jean-Claude Baron; Jeffrey W Dalley; Tim D Fryer; Franklin I Aigbirhio Journal: J Cereb Blood Flow Metab Date: 2011-07-13 Impact factor: 6.200
Authors: Paul R A Stokes; Paul Shotbolt; Mitul A Mehta; Eric Turkheimer; Aaf Benecke; Caroline Copeland; Federico E Turkheimer; Anne R Lingford-Hughes; Oliver D Howes Journal: Neuropsychopharmacology Date: 2012-10-24 Impact factor: 7.853